AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800
Debt
Debt-to-Equity Ratio0.82
Current Ratio3.32
Quick Ratio2.81
Price-To-Earnings
Trailing P/E Ratio-177.42
Forward P/E Ratio-148.65
P/E GrowthN/A
Sales & Book Value
Annual Sales$60.43 million
Price / Sales31.45
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book74.32
Profitability
EPS (Most Recent Fiscal Year)($0.31)
Net Income$-10,440,000.00
Net Margins-18.83%
Return on Equity-61.66%
Return on Assets-21.29%
Miscellaneous
Employees199
Outstanding Shares34,560,000
Market Cap$1,900.81
AxoGen, Inc Common Stock (NASDAQ:AXGN) Frequently Asked Questions
What is AxoGen, Inc Common Stock's stock symbol?
AxoGen, Inc Common Stock trades on the NASDAQ under the ticker symbol "AXGN."
How were AxoGen, Inc Common Stock's earnings last quarter?
AxoGen, Inc Common Stock (NASDAQ:AXGN) announced its quarterly earnings data on Monday, April, 30th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). The medical equipment provider earned $17.30 million during the quarter, compared to analysts' expectations of $17.16 million. AxoGen, Inc Common Stock had a negative return on equity of 61.66% and a negative net margin of 18.83%. AxoGen, Inc Common Stock's revenue was up 41.8% on a year-over-year basis. View AxoGen, Inc Common Stock's Earnings History.
What price target have analysts set for AXGN?
8 brokerages have issued 12-month price targets for AxoGen, Inc Common Stock's shares. Their predictions range from $21.00 to $70.00. On average, they expect AxoGen, Inc Common Stock's share price to reach $41.2857 in the next year. This suggests that the stock has a possible downside of 24.9%. View Analyst Ratings for AxoGen, Inc Common Stock.
What is the consensus analysts' recommendation for AxoGen, Inc Common Stock?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen, Inc Common Stock in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of AxoGen, Inc Common Stock's key competitors?
Some companies that are related to AxoGen, Inc Common Stock include Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), CONMED (CNMD), NxStage Medical (NXTM), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), BioLife Solutions (BLFS), Vision Sciences (CGNT), Rockwell Medical (RMTI), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES) and Zynex Inc. common stock (ZYXI).
Who are AxoGen, Inc Common Stock's key executives?
AxoGen, Inc Common Stock's management team includes the folowing people:
- Ms. Karen Zaderej, Pres, CEO & Chairman (Age 56)
- Mr. Peter J. Mariani, Chief Financial Officer (Age 54)
- Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel, Sr. VP of Bus. Devel. & Director (Age 56)
- Mr. Shawn F. McCarrey, Sr. VP of Sales (Age 60)
- Mr. Jon S. Gingrich, Chief Commercial Officer (Age 49)
Has AxoGen, Inc Common Stock been receiving favorable news coverage?
News coverage about AXGN stock has been trending somewhat positive this week, Accern reports. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AxoGen, Inc Common Stock earned a coverage optimism score of 0.21 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 46.01 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are AxoGen, Inc Common Stock's major shareholders?
AxoGen, Inc Common Stock's stock is owned by a number of of institutional and retail investors. Top institutional investors include Fred Alger Management Inc. (1.18%), Columbia Partners L L C Investment Management (0.54%), Pennsylvania Trust Co (0.43%), Essex Investment Management Co. LLC (0.30%), Dubuque Bank & Trust Co. (0.02%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own AxoGen, Inc Common Stock stock include Amy Mcbride Wendell, Guido J Neels, James E Flynn, Jamie Mark Grooms, John P Engels, Joseph M Mandato, Karen L Zaderej, Peter J Mariani, Robert James Rudelius and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen, Inc Common Stock.
Which institutional investors are selling AxoGen, Inc Common Stock stock?
AXGN stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Columbia Partners L L C Investment Management. Company insiders that have sold AxoGen, Inc Common Stock company stock in the last year include Guido J Neels, Jamie Mark Grooms, Robert James Rudelius and Shawn F Mccarrey. View Insider Buying and Selling for AxoGen, Inc Common Stock.
Which institutional investors are buying AxoGen, Inc Common Stock stock?
AXGN stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Pennsylvania Trust Co, Dubuque Bank & Trust Co., Xact Kapitalforvaltning AB, Amalgamated Bank, Campbell & CO Investment Adviser LLC, Hartford Investment Management Co. and Bank of Montreal Can. Company insiders that have bought AxoGen, Inc Common Stock stock in the last two years include Amy Mcbride Wendell, John P Engels, Karen L Zaderej and Peter J Mariani. View Insider Buying and Selling for AxoGen, Inc Common Stock.
How do I buy shares of AxoGen, Inc Common Stock?
Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AxoGen, Inc Common Stock's stock price today?
One share of AXGN stock can currently be purchased for approximately $55.00.
How big of a company is AxoGen, Inc Common Stock?
AxoGen, Inc Common Stock has a market capitalization of $1.90 billion and generates $60.43 million in revenue each year. The medical equipment provider earns $-10,440,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. AxoGen, Inc Common Stock employs 199 workers across the globe.
How can I contact AxoGen, Inc Common Stock?
AxoGen, Inc Common Stock's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]
MarketBeat Community Rating for AxoGen, Inc Common Stock (NASDAQ AXGN)
MarketBeat's community ratings are surveys of what our community members think about AxoGen, Inc Common Stock and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
